Pacific released a research report on April 25 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating, and the target price was 18.42 yuan. The main reasons for the rating include: 1) Q1 revenue growth rate was steady, and performance exceeded expectations; 2) gross margin increased and profitability improved; 3) Digitalini achieved commercialization and continued implementation of the innovation pipeline. (Mainichi Keizai Shimbun)
太平洋4月25日发布研报称，给予京新药业（002020.SZ）买入评级，目标价格为18.42元。评级理由主要包括：1）Q1收入增速稳健，业绩超预期；2）毛利率提升，盈利能力改善；3）地达西尼实现商业化，创新管线持续兑现。（每日经济新闻）
Pacific released a research report on April 25 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating, and the target price was 18.42 yuan. The main reasons for the rating include: 1) Q1 revenue growth rate was steady, and performance e
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.